Q4 2024 Earnings Call Transcript March 27, 2025 PDS Biotechnology Corporation beats earnings expectations. Reported EPS is ...

An overview of the advertising technology (adtech) industry and relevant US and EU privacy laws, including the Federal Trade ...

Q4 2024 Earnings Call Transcript March 31, 2025 Talphera, Inc. beats earnings expectations. Reported EPS is $-0.07, expectations were $-0.21. Operator: Welcome to the Talphera Fourth Quarter and Full ...

Good morning and welcome to PDS Biotech's 4th quarter in full year 2024 earnings conference call. Thank you, operator. Good morning, everyone, and welcome to PDS Biotech's 2024 results and clinical ...

Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ETCompany ParticipantsBruce Mackle - LifeSci Advisors, ...

Rodrigo Barbosa, President and CEO of Aura commented, “Reflecting on another year of disciplined execution and strategic ...

The interesting approach here is to look at submarkets and break them down into three life cycle blocks. Up-and-Coming (the ...

ZOLAR is a first-in-human, proof-of-concept and biodistribution trial that uses positron emission tomography (PET) to evaluate olaratumab, a monoclonal antibody, as a therapeutic radiopharmaceutical ...

BioAtla is extending its runway beyond key clinical readouts in 1H 2026 by restructuring and realigning resources, which ...

“We achieved significant progress across ... potentially best-in-class profile. In the updated dataset, safety was consistent with prior results, and APG777 demonstrated a favorable pharmacodynamic ...

Why Alloy Development, Neutral, and Onx are among Fast Company’s Most Innovative Companies in urban development and real ...